MARK T FLEMING MD NPI 1457383663

NPI Details

Mark T Fleming, MD is a hematology and oncology internal medicine in Hampton, VA with 27 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Mark T Fleming, MD NPI is 1457383663. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF TOLEDO COLLEGE OF MEDICINE
Graduation Year:1999

The provider's business location address is:

3000 COLISEUM DR
SUITE 104
HAMPTON, VA
ZIP 23666-963
Phone: (757) 827-9400
Fax: (757) 827-9320

The NPI 1457383663 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Lipase (fat enzyme) level (HCPCS:83690)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection, iron dextran, 50 mg (HCPCS:J1750)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Ferritin (blood protein) level (HCPCS:82728)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Telephone medical discussion with physician, 5-10 minutes (HCPCS:99441)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Measurement of substance using immunoassay technique (HCPCS:83520)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Urinalysis, manual test (HCPCS:81002)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Blood test, clotting time (HCPCS:85610)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Protein measurement, serum (HCPCS:84165)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Unclassified drugs (HCPCS:J3490)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Folic acid level, serum (HCPCS:82746)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Amylase (enzyme) level (HCPCS:82150)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
• Telephone medical discussion with physician, 21-30 minutes (HCPCS:99443)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Injection of drug or substance into vein (HCPCS:96374)
• Magnesium level (HCPCS:83735)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)

The enumeration date for this NPI number is 7/7/2006 and was last updated on 3/7/2023.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.